Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Archives of Dermatological Research
Published in: Archives of Dermatological Research 2/2017

Open Access 01-03-2017 | Original Paper

Increase in circulating sphingosine-1-phosphate and decrease in ceramide levels in psoriatic patients

Authors: Hanna Myśliwiec, Anna Baran, Ewa Harasim-Symbor, Barbara Choromańska, Piotr Myśliwiec, Anna Justyna Milewska, Adrian Chabowski, Iwona Flisiak

Published in: Archives of Dermatological Research | Issue 2/2017

Login to get access

Abstract

Psoriasis is characterized by hyperproliferation, deregulated differentiation and impaired apoptosis of keratinocytes. Mechanisms of lipid profile disturbances and metabolic syndrome in the psoriatic patients are still not fully understood. Sphingolipids, namely ceramides (CER) and sphingosine-1-phosphate (S1P) are signal molecules which can regulate cell growth, apoptosis and immune reactions. The aim of the study was to evaluate circulating CER and S1P levels in plaque-type psoriasis and their associations with the disease activity, inflammatory or metabolic markers and the presence of psoriatic comorbidities. Eighty-five patients with exacerbated plaque-type psoriasis and thirty-two healthy controls were enrolled. Serum CER and S1P concentrations before the treatment were examined. General patient characteristics included: PASI (Psoriasis Area and Severity Index), BMI (Body Mass Index), inflammatory and biochemical markers, lipid profile and presence of psoriatic comorbidities. Total serum concentration of CER was significantly decreased (p = 0.02) and concomitantly S1P levels significantly increased (p = 0.002) in psoriatic patients compared to the healthy control group. Among patients with psoriasis no significant correlations with the disease activity and inflammation markers were observed and only patients with psoriatic arthritis had significantly higher CER total concentration. Serum sphingolipid disturbances in psoriatic patients were observed. Decreased total CER and increased S1P serum levels may reflect their epidermal altered composition and metabolism. Patients with psoriatic arthritis have higher CER levels than psoriasis with skin involvement only. It might provide additional predictive value for psoriatic arthritis and may convey higher risk of metabolic and cardiovascular disease development in this group of patients.
Literature
1.
Akhyani M, Ehsani AH, Robati RM, Robati AM (2007) The lipid profile in psoriasis: a controlled study. J Eur Acad Dermatol Venereol 21:1330–1332CrossRefPubMed
2.
Alessandrini F, Stachowitz S, Ring J, Behrendt H (2001) The level of prosaposin is decreased in the skin of patients with psoriasis vulgaris. J Invest Dermatol 116:394–400CrossRefPubMed
3.
Bikman BT (2012) A role for sphingolipids in the pathophysiology of obesity-induced inflammation. Cell Mol Life Sci 69:2135–2146CrossRefPubMed
4.
Bismuth J, Lin P, Yao Q, Chen C (2008) Ceramide: a common pathway for atherosclerosis? Atherosclerosis 196:497–504CrossRefPubMed
5.
6.
Brinkmann V, Davis MD, Heise CE, Albert R, Cottens S, Hof R, Bruns C, Prieschl E, Baumruker T, Hiestand P, Foster CA, Zollinger M, Lynch KR (2002) The immune modulator FTY20 targets sphingosine 1-phosphate receptors. J Biol Chem 277:21453–21457CrossRefPubMed
7.
Chaurasia B, Summers SA (2015) Ceramides—Lipotoxic inducers of metabolic disorders. Trends Endocrinol Metab 26:538–550CrossRefPubMed
8.
Checa A, Xu N, Sar DG, Haeggstrom JZ, Stahle M, Wheelock CE (2015) Circulating levels of sphingosine-1-phosphate are elevated in severe, but not mild psoriasis and are unresponsive to anti-TNF-α treatment. Sci Rep. doi:10.​1038/​srep12017
9.
Chiricozzi A, Raimondo A, Lembo S, Fausti F, Dini V, Costanzo A, Monfrecola G, Balato N, Ayala F, Romanelli M, Balato A (2016) Crosstalk between skin inflammation and adipose tissue-derived products: pathogenic evidence linking psoriasis to increased adiposity. Expert Rev Clin Immunol 12:1299–1308CrossRefPubMed
10.
Cho Y, Lew BL, Seong K, Kim NI (2004) An inverse relationship between ceramide synthesis and clinical severity in patients with psoriasis. J Korean Med Sci 19:859–863CrossRefPubMedPubMedCentral
11.
Deutschman DH, Carstens JS, Klepper RL, Smith WS, Page MT, Young TR, Gleason LA, Nakajima N, Sabbadini RA (2003) Predicting obstructive coronary artery disease with serum sphingosine-1-phosphate. Am Heart J 146:62–68CrossRefPubMed
12.
Edson-Heredia E, Zhu B, Lefevre C, Wang M, Barrett A, Bushe CJ, Cox A, Wu JJ, Maeda-Chubachi T (2015) Prevalence and incidence rates of cardiovascular, autoimmune, and other diseases in patients with psoriatic or psoriatic arthritis: a retrospective study using Clinical Practice Research Datalink. J Eur Acad Dermatol Venereol 29:955–963CrossRefPubMed
13.
El Asmi MA, Zidi W, Mebazaa A, Zayani Y, Ayadi I, Feki M, Ben Osman A, Kaabachi N (2014) Serum lipid level in Tunisian patients with psoriasis. Clin Lab 60:1043–1047PubMed
14.
Gisondi P, Tesari G, Ci-onti A, Piaserico S, Schianchi S, Peserico A, Giannetti A, Girolomoni G (2007) Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 157:68–73CrossRefPubMed
15.
16.
Grammatikos G, Ferreiròs N, Waidmann O, Bon D, Schroeter S, Koch A, Herrmann E, Zeuzem S, Kronenberger B, Pfeilschifter J (2015) Serum sphingolipid variations associate with hepatic decompensation and survival in patients with cirrhosis. PLoS One 10(9):e0138130CrossRefPubMedPubMedCentral
17.
Grammatikos G, Muhle C, Ferreiros N, Schroeter S, Bogdanou D, Schwalm S, Hintereder G, Kornhuber J, Zeuzem S, Sarrazin C, Pfeilschifter J (2014) Serum acid sphingomyelinase is upregulated in chronic hepatitis C infection and non alcoholic fatty liver disease. Biochim Biophys Acta 1841:1012–1020CrossRefPubMed
18.
Herzinger T, Kleuser B, Schafer-Korting M, Korting HC (2007) Sphingosine-1-phosphate signaling and the skin. Am J Clin Dermatol 8:329–336CrossRefPubMed
19.
Klein RL, Hammad SM, Baker NL, Hunt KJ, Al Gadban MM, Cleary PA, Virella G, Lopes-Virella MF, DCCT/EDIC Research Group (2014) Decreased plasma levels of select very long chain ceramide species are associated with the development of nephropathy in type 1 diabetes. Metabolism 63:1287–1295CrossRefPubMed
20.
Kosinska MK, Liebisch G, Lochnit G, Wilhelm J, Klein H, Kaesser U, Lasczkowski G, Rickert M, Schmitz G, Steinmeyer J (2014) Sphingolipids in human synovial fluid—a lipidomic study. PLoS One 9(3):e91769CrossRefPubMedPubMedCentral
21.
Książek M, Chacińska M, Chabowski A, Baranowski M (2015) Sources, metabolism, and regulation of circulating sphingosine-1-phosphate. J Lipid Res 56:1271–1281CrossRefPubMedPubMedCentral
22.
23.
Lai WQ, Chia FL, Leung BP (2012) Sphingosine kinase and sphingosine-1-phosphate receptors: novel therapeutic targets of rheumatoid arthritis Future. Med Chem 4:727–733
24.
Laporte M, Galand P, Fokan D, de Graef C, Heenen M (2000) Apoptosis in established and healing psoriasis. Dermatology 200:314–316CrossRefPubMed
25.
Lew BL, Cho Y, Kim J, Sim WY, Kim NI (2006) Ceramides and cell signaling molecules in psoriatic epidermis: reduced levels of ceramides, PKC-α, and JNK. J Korean Med Sci 21:95–99CrossRefPubMedPubMedCentral
26.
Li X, Becker KA, Zhang Y (2010) Ceramide in redox signaling and cardiovascular diseases. Cell Physiol Biochem 26:41–48CrossRefPubMed
27.
Li N, Zhang F (2016) Implication of sphingosine-1-phosphate in cardiovascular regulation. Front Biosci (Landmark Ed) 21:1296–1313CrossRef
28.
Lopez X, Goldfine AB, Holland WL, Gordillo R, Scherer PE (2013) Plasma Ceramides are elevated in female children and adolescents with type 2 diabetes. J Pediatr Endocrinol Metab 26:995–998CrossRefPubMed
29.
Lowes MA, Bowcock AM, Krueger JG (2007) Pathogenesis and therapy of psoriasis. Nature 445:866–873CrossRefPubMed
30.
Majumdar I, Mastrandrea LD (2012) Serum sphingolipids and inflammatory mediators in adolescents at risk for metabolic syndrome. Endocrine 41:442–449CrossRefPubMed
31.
32.
Mechtcheriakova D, Wlachos A, Sobanov J, Kopp T, Reuschel R, Bornancin F, Cai R, Zemann B, Urtz N, Stingl G, Zlabinger G, Woisetschlager M, Baumruker T, Bilich A (2007) Sphingosine 1-phosphate phosphatase 2 is induced during inflammatory responses. Cell Signal 19:748–760CrossRefPubMed
33.
Migita K, Honda S, Yamasaki S, Hirai Y, Fukuda T, Aoyagi T, Kita M, Ida H, Tsukada T, Kawakami A, Kawabe Y, Eguchi K (2000) Regulation of rheumatoid synovial cell growth by ceramide. Biochem Biophys Res Commun 269:70–75CrossRefPubMed
34.
Mizushima N, Kohsaka H, Miyasaka N (1998) Ceramide, a mediator of interleukin 1, tumor necrosis factor alpha, as well as Fas receptor signaling, induces apoptosis of rheumatoid arthritis synovial cells. Ann Rheum Dis 57:495–499CrossRefPubMedPubMedCentral
35.
Moon SH, Kim JY, Song EH, Shin MK, Cho YH, Kim NI (2013) Altered levels of sphingosine and sphinganine on psoriatic epidermis. Ann Dermatol 25:321–326CrossRefPubMedPubMedCentral
36.
37.
Raychaudhuri SP, Farber EM (2001) The prevalence of psoriasis in the world. J Eur Acad Dermatol Venereol 15:16–17CrossRefPubMed
38.
Samad F, Hester KD, Yang G, Hannun YA, Bielawski J (2006) Altered adipose and plasma sphingolipid metabolism in obesity: a potential mechanism for cardiovascular and metabolic risk. Diabetes 55:2579–2587CrossRefPubMed
39.
Schmitt J, Wozel G (2005) The Psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology 210:194–199CrossRefPubMed
40.
Tawada C, Kanoh H, Nakamura M, Mizutani Y, Fujisawa T, Banno Y, Seishima M (2014) Interferon-γ decreases ceramides with long-chain fatty acids: possible involvement in atopic dermatitis and psoriasis. J Invest Dermatol 134:712–718CrossRefPubMed
41.
Tsai HC, Han MH (2016) Sphingosine-1-phosphate (S1P) and S1P signaling pathway: therapeutic targets in autoimmunity and inflammation. Drugs 76:1067–1079CrossRefPubMed
42.
Wrone-Smith T, Mitra RS, Thompson CB, Jasty R, Castle VP, Nickoloff BJ (1997) Keratinocytes derived from psoriatic plaques are resistant to apoptosis compared with normal skin. Am J Pathol 151:1321–1329PubMedPubMedCentral
43.
Yu J, Pan W, Shi R, Yang T, Li Y, Bai Y, Schuchman EH, He X, Zhang G (2015) Ceramide is upregulated and associated with mortality in patients with chronic heart failure. Can J Cardiol 31:357–363CrossRefPubMed
Metadata
Title
Increase in circulating sphingosine-1-phosphate and decrease in ceramide levels in psoriatic patients
Authors
Hanna Myśliwiec
Anna Baran
Ewa Harasim-Symbor
Barbara Choromańska
Piotr Myśliwiec
Anna Justyna Milewska
Adrian Chabowski
Iwona Flisiak
Publication date
01-03-2017
Publisher
Springer Berlin Heidelberg
Published in
Archives of Dermatological Research / Issue 2/2017
Print ISSN: 0340-3696
Electronic ISSN: 1432-069X
DOI
https://doi.org/10.1007/s00403-016-1709-9

Other articles of this Issue 2/2017

Archives of Dermatological Research 2/2017 Go to the issue

Original Paper

Immunolocalization of substance P and NK-1 receptor in vascular anomalies

Original Paper

MiR-21 and miR-205 are induced in invasive cutaneous squamous cell carcinomas

Original Paper

Investigation of 36 non-HLA (human leucocyte antigen) psoriasis susceptibility loci in a psoriatic arthritis cohort

Original Paper

Senescence in the lesional fibroblasts of non-segmental vitiligo patients

Original Paper

N-Acetylglutaminoyl-S-farnesyl-l-cysteine (SIG-1191): an anti-inflammatory molecule that increases the expression of the aquaglyceroporin, aquaporin-3, in human keratinocytes

Original Paper

In vitro cultured fetal fibroblasts have myofibroblast-associated characteristics and produce a fibrotic-like environment upon stimulation with TGF-β1: Is there a thin line between fetal scarless healing and fibrosis?